First Allied Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

First Allied Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,293	Closed	-$207K	–	1237
2020 Q2	$207K	Buy	+1,293	New	+$176K	0.01%	993
2019 Q2	–	Sell	-2,754	Closed	-$328K	–	1242
2019 Q1	$328K	Buy	2,754 +384	+16%	+$49.4K	0.01%	827
2018 Q4	$258K	Hold	2,370	–	–	0.01%	842
2018 Q3	$382K	Buy	2,370 +306	+15%	+$41.8K	0.01%	813
2018 Q2	$272K	Sell	2,064 -5,000	-71%	-$472K	0.01%	920
2018 Q1	$524K	Sell	7,064 -1,977	-22%	-$132K	0.02%	650
2017 Q4	$503K	Hold	9,041	–	–	0.02%	653
2017 Q3	$410K	Buy	9,041 +15	+0.2%	+$599	0.02%	686
2017 Q2	$304K	Sell	9,026 -600	-6%	-$19.5K	0.01%	820
2017 Q1	$285K	Buy	9,626 +600	+7%	+$18.6K	0.01%	808
2016 Q4	$248K	Buy	9,026 +26	+0.3%	+$1.04K	0.01%	883
2016 Q3	$553K	Sell	9,000 -3,800	-30%	-$115K	0.03%	535
2016 Q2	$245K	Buy	12,800 +800	+7%	+$14.8K	0.01%	838
2016 Q1	$234K	Sell	12,000 -100	-0.8%	-$1.75K	0.01%	841
2015 Q4	$467K	Buy	12,100 +100	+0.8%	+$3.24K	0.02%	602
2015 Q3	$385K	Sell	12,000 -1,000	-8%	-$33.9K	0.02%	647
2015 Q2	$396K	Sell	13,000 -6,600	-34%	-$135K	0.02%	707
2015 Q1	$260K	Hold	19,600	–	–	0.02%	847
2014 Q4	$284K	Buy	19,600 +6,000	+44%	+$102K	0.02%	786
2014 Q3	$287K	Sell	13,600 -74	-0.5%	-$1.67K	0.02%	746
2014 Q2	$407K	Sell	13,674 -34	-0.2%	-$1.07K	0.03%	600
2014 Q1	$330K	Buy	13,708 +54	+0.4%	+$1.38K	0.02%	683
2013 Q4	$278K	Buy	13,654 +4,600	+51%	+$137K	0.02%	693
2013 Q3	$428K	Sell	9,054 -4,000	-31%	-$154K	0.02%	600
2013 Q2	$497K	Buy	+13,054	New	+$467K	0.04%	484

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

First Allied Advisory Services's SRPT Position: Q3 2020 in Review

First Allied Advisory Services sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 1,293 shares — an estimated $207K sold.

First Allied Advisory Services first reported a position in SRPT in Q2 2013 and held it in 25 quarters. The position peaked at $553K in Q3 2016. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

First Allied Advisory Services reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
First Allied Advisory Services sold 1,293 Sarepta Therapeutics shares in Q3 2020, an estimated $207K.
First Allied Advisory Services first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 25 quarters.
First Allied Advisory Services's Sarepta Therapeutics position peaked at $553K in Q3 2016.
403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.